Just imagine you were diagnosed with a cancerous tumor, and your doctor told you that his/her proposed treatment could reduce the size of your tumor by 30 percent, but at the same time increase your chances of developing secondary tumors by a whopping 300 percent!
That is exactly what is demonstrated in recent research (at Harvard and MD Anderson Cancer Centers), and published in conventional Oncology Journals! The history of conventional anti-cancer therapies is replete with cases where the treatment turned out to be far more devastating than the disease itself.
A 2012 study, supported by the National Institutes of Health (NIH), sheds new light on why the effectiveness of a relatively new class of cancer fighting (anti-angiogenic) drugs is actually short-lived, and can turn into a frightening scenario, very likely triggering fatal consequences. This study was published in the January 17, 2012 issue of Cancer Cell.
These drugs act by cutting off the blood supply to the tumors. Scientists and Oncologists from around the world made the shortsighted assumption that by cutting off a tumor’s life support system, they could achieve a successful and permanent tumor regression…WRONG! Little did they know that this would open Pandora’s Box and create a cancer nightmare! This same study described in Cancer Cell found that a group of little-explored cells (called pericytes), which are part of every primary cancerous tumor, likely serve as important gatekeepers against cancer progression and metastasis. In this investigation, Raghu Kalluri, M.D., PhD, professor of Medicine at Harvard Medical School, had actually intended to find out if killing pericytes could inhibit growth of tumors. They knew that the pericytes are important in supporting the growth of new blood vessels. What they discovered instead was both startling and disturbing: pericytes actually help PREVENT metastasis!
Dr. Kalluri and his colleagues found that by depleting the pericyte numbers by 60 percent in breast cancer tumors, they saw a 30 percent decrease in tumor volumes over 25 days. Conventional “medical wisdom” hailed this as a “breakthrough in cancer treatment.” However, the researchers also discovered that by destroying pericytes by 60-70 percent, the number of secondary lung tumors increased threefold!
These entire findings question the very argument that is pushed on unsuspecting cancer patients by most Oncology medical professionals; is treatment-caused tumor regression a desirable objective?
What is even more distressing is the high cost of these new drugs. In addition to that, other research shows an increased incidence of perforated bowels, perforated stomachs and heart attacks!
Open minded Physicians have long maintained the importance of focusing on treating the whole person, and not just the tumor. When the therapy destroys, or does significant damage to the patient, it cannot be beneficial! For some reason, conventional Oncologists have not caught on to this idea and continue to focus their efforts on tumor shrinkage, at all costs.
1. Ribatti, Domenico, Dept. of Human Anatomy & Histology, University of Bari Medical School, Bari, Italy, “The Inefficacy of Antiangiogenic Therapy”, Journal of Angiogenesis Research, 2010,2:27.
2. Kalluri, Raghu, M.D., PhD, “Study Shows How a Group of Tumor Cells Prevent Cancer Spread-Paradoxical discovery finds that pericyte cells help prevent metastasis”, Cancer Cell , January 17,2012.